About
VX Pharma
Who are we?
Vx Pharma was founded by Mark Fyvie (PhD) an experienced biopharma entrepreneur with extensive skills across the full value chain of therapeutics development. Mark recently sold the SMO and Super-Site operations to focus fully on the new business model of the Company, and has partnered with a successful financial services veteran, to launch the new business from Oxford (U.K). Together they are focusing on building on their unique Fractional IP Resourcing model, with a select network of highly experienced associates who cover the full value chain of the new business services.
Our history
Vx Pharma was formally founded in 2010 and with development finance from the Industrial Development Corporation (IDC) constructed a new state of the art facility to activate its Site and SMO operations.
The IDC divested in early 2018 via an investment by the clinical pathology group Ampath Laboratories, allowing the business to consider its future growth strategy with a much broader vision. In 2020, the SMO and Site operations of the business were sold and the founder acquired the intellectual assets of the business. During the decade as a site-model business, Vx Pharma successfully delivered hundreds of clinical studies across all phases, serving many of the world’s blue-chip Large Pharma businesses.
Today we deliver a business model niche at the intersection of clinical development, business strategy and funding
Our Broader Vision
We engage, on a company-partnership level, with quality Emerging Biopharma businesses with mature platform technologies and promising product pipelines. Although there are several strategic paths to expedite the development of a product portfolio, we can lead the way and guide the client across all phases of drug development whilst assisting to resource this journey through our unique Capital Solutions.
In addition to our core business model we also help our Large Pharma clients find cost effective Clinical Development Solutions via our network of exclusive execution partners, with which we have pre-negotiated preferential deals. We have capabilities across all the stages of the clinical journey, starting with rigorous Business Strategy and Planning.
Our Clients
